Can sildenafil reduce Alzheimer’s risk, and what does the research show in Europe?

Sildenafil and Alzheimer’s explained: PDE5 inhibition, cerebral blood flow, observational data, dementia risk, and clinical interpretation.

In this episode, we examine studies suggesting a possible association between sildenafil use and reduced Alzheimer’s risk, and how doctors interpret these findings under EU medical guidance.

You’ll learn:

• What sildenafil is (a phosphodiesterase type 5 inhibitor)

• How PDE5 inhibitors affect nitric oxide signalling and blood flow

• The difference between observational associations and proven prevention

• Why improved vascular health may influence cognitive outcomes

• Current limitations of available studies

• Why sildenafil is not prescribed to prevent dementia

• Situations where medication requests may be declined without approved indication

We explain how doctors assess cardiovascular risk, erectile dysfunction history, medication interactions (including nitrate use), cognitive symptoms, and overall health during an online consultation in the EU. Current evidence does not establish sildenafil as a preventive treatment for Alzheimer’s disease.

This episode reflects the clinical standards used by Mobi Doctor, where sexual health and cardiovascular consultations are reviewed by a registered physician in line with EU prescribing guidance.

Read the full guide and transcript here:

https://www.mobidoctor.eu/blog/sildenafil-may-help-reduce-alzheimers-risk